Skip to main content

Table 1 Patient characteristics at enrolment in Arm A vs. Arm B

From: A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

  Arm A
Paclitaxel
N = 30
Arm B
Paclitaxel + Sorafenib
N = 30
Age, mean (SD), years 59.4 (10.4) 59.0 (9.6)
ECOG status, n (%)
 0 23 (76%) 19 (61%)
 I 7 (24%) 11 (39%)
Number of metastatic sites
 < 2 14 (46.7) 9 (30)
 > = 2 16 (53.3) 21 (70)
Hormone receptor status, n (%)
 ER+ or PR+ 25 (83.3) 24 (80.0)
 ER- and PR- 5 (16.7) 6 (20.0)
Pre-treatment with bevacizumab
 No 7 (23.3) 8 (26.7)
 Yes 23 (76.7) 22 (73.3)
Line of therapy, n (%)
 Second-line 20 (66.6) 21 (70.0)
 Third-line 10 (33.3) 9 (30.0)
Taxan pretreatment n (%)
 No 23 (76.7) 20 (66.7)
 Yes 7 (23.3) 10 (33.3)